Bristol-Myers Squibb buying Celgene in $74B deal

First few lines of the article discuss purchase of drugs that are about to hit the market:

SUMMIT, N.J. (AP) - Bristol-Myers Squibb is spending $74 billion on fellow drugmaker Celgene in a deal aimed at stocking the combined company’s development pipeline with cancer, immunology and cardiovascular treatments.

Bristol would gain the cancer treatment Revlimid in the cash-and-stock deal announced Thursday, as well as inflammatory disease treatments and several products close to launching.

https://www.washingtontimes.com/news/2019/jan/3/bristol-myers-squibb-buying-celgene-in-74b-deal/